Grifols, S.A. (GRFS) Stock

Grifols, S.A., headquartered in Barcelona, Spain, specializes in the procurement, manufacturing, preparation, and distribution of therapeutic products, primarily focusing on hemoderivatives. Established in 1940, the company operates through several divisions including Bioscience, Hospital, Diagnostic, Bio Supplies, and Others. The Bioscience division is dedicated to researching, developing, producing, and marketing plasma-derived medicines and innovative solutions to address a wide spectrum of chronic, rare, prevalent, and life-threatening diseases. These offerings include immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins.

In addition to its Bioscience division, Grifols' Hospital division provides a range of non-biological pharmaceutical products, clinical nutrition, intravenous therapy, and medical devices. The Diagnostic division focuses on developing and commercializing diagnostic products that span the entire healthcare continuum from prevention and screening to diagnosis, prognosis, and disease monitoring. Meanwhile, the Bio Supplies division supplies biological materials critical for life-science research, clinical trials, and the production of pharmaceutical and diagnostic products.

Grifols serves a diverse customer base that includes healthcare providers, wholesalers, distributors, group purchasing organizations, blood banks, hospitals, care institutions, and national health systems worldwide. The company's commitment to innovation is underscored by its technology collaboration agreement with Mondragon, reflecting its strategic efforts to advance healthcare solutions through collaborative research and development initiatives. With a longstanding history and global reach, Grifols continues to expand its capabilities and enhance its offerings to meet the evolving needs of patients and healthcare professionals globally.